IPSC News and Press, Century Therapeutics Inc.

2026-07-09 13:41:14 ET The last time I spoke about Century Therapeutics ( IPSC ) it was with a Seeking Alpha article entitled " Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101 ." With respect to this article, I noted that the company had released a...

PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced ...

2026-06-09 05:18:04 ET More on biotechnology stocks: Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript Tango Therapeutics, Inc. (TNGX) Discusses Promising C...

Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical models Allo-Evasion™ 5.0 maintains insulin secretion and maintained normo...

2026-06-08 10:59:18 ET More on Health Care stocks AI Revolutionizing Biopharma: Faster, Better, Cheaper Trump's Psychedelics Stance Reignites Sector - How Investors Can Benefit IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech Tech outpaces ev...

NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company’s Boar...

2026-05-13 08:21:37 ET More on Century Therapeutics Century Therapeutics: A Biotech With Interesting Optionality Opportunities Small-Cap healthcare stocks ranked by quant ratings after earnings season Century Therapeutics GAAP EPS of -$0.14, revenue of $109.2M ...

CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY&...

PHILADELPHIA, April 30, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced the c...

2026-04-24 07:22:01 ET Investment Thesis I value Century Therapeutics (NASDAQ: IPSC) with a speculative buy rating. The company has undergone a pivotal restructuring in its pipeline, deprioritizing oncology programs in favor of autoimmune CAR cells and the innovative CNTY-813, treat...